AbbVie Inc. (ABBV)
5 Dividend Powerhouses That Could Transform Your Portfolio Into a Wealth-Building Machine
Building wealth through dividends requires more than chasing high yields. The path to “getting rich” combines meaningful current income with consistent dividend growth, backed by sustainable business fundamentals.
AbbVie Slipped Below 50-Day SMA Last Week: How to Play the Stock
AbbVie dips below its 50-day SMA, but strong immunology momentum and a resilient long-term trend keep the story compelling.
Proven Income Generators: Ranking the Most Reliable Dividend Growth Stocks
Dividend investing rewards patience. The best dividend stocks don't just pay consistently—they raise payouts year after year, compounding income for shareholders who stay the course.
Dividend Powerhouses: 3 Blue-Chip Stocks Built for the Long Haul
The wall of worry continues to grow as investors race into 2026. Concentration risk is one that may not get talked about enough.
Here's How AbbVie's Oncology Drugs are Aiding Top-line Growth
ABBV's expanding oncology lineup, spanning new solid tumor drugs and rising Venclexta sales, is helping drive steady top-line growth.
AbbVie: Unique Mix Of Growth And Value
AbbVie earns a Strong Buy rating, driven by exceptional execution post-Humira patent cliff and robust 2025 share price outperformance. Skyrizi and Rinvoq are rapidly replacing Humira, delivering 47% and 35% YoY growth in Q3 2025, with patent protection into the 2030s. ABBV's business mix is diversified, with immunology and neuroscience segments together driving double-digit revenue growth and supporting strong EPS prospects.
This Dividend Pharma Giant Yielding 2.9% Just Got a Big Vote of Confidence
Healthcare stocks have lagged the broader market for the past three years, weighed down by post-COVID earnings volatility, policy uncertainties around drug pricing, and a surge in tech-driven gains from the AI boom.
AbbVie (ABBV) Falls More Steeply Than Broader Market: What Investors Need to Know
AbbVie (ABBV) concluded the recent trading session at $223.12, signifying a -1.31% move from its prior day's close.
How Strong Is AbbVie's Immunology Franchise After Humira's LOE?
ABBV rebounds after Humira's LOE as soaring Skyrizi and Rinvoq sales drive a powerful immunology comeback.
AbbVie Inc. (ABBV) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
AbbVie Inc. (ABBV) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
AbbVie: Increased Outlook For 2025 And Expansions Merit Continued "Strong Buy" Rating
AbbVie (ABBV) remains a "Strong Buy" due to robust growth in immunology and neuroscience portfolios, offsetting Humira's decline. ABBV's oncology segment is poised for expansion with trispecific antibody ISB 2001 for relapsed/refractory multiple myeloma and Epkinly's third FDA approval. Epkinly's rapid sales growth and multiple ongoing phase 3 studies signal further upside potential in ABBV's oncology pipeline.
